Welcome to Mergermarket's Annual Life Sciences And Healthcare M&A Forum
Within the life sciences industry, market observers are expecting biotechnology firms to be a standout performer in M&A over the next 12 months. This would represent a significant turnaround in dealmaking considering the subsector accounted for only 31% of total PMB (Pharma, Medical & Biotech) activity in 2016.
The new Trump administration's plans for repealing the Affordable Care Act have created uncertainty around hospital M&A, which saw many regional and chain operators merge with one another or with physician groups, digital health firms, and service providers. Similarly, health firms of all sizes have sought out acquisitions of digital health companies that provide a range of services from data and analytics to healthcare IT partly because of the move to value-based care over fee-for-a-service.
This event will feature esteemed panelists as they discuss the latest issues and trends that are impacting deal activity and financing in the healthcare and life sciences industry.